Zoetis (ZTS) Expected to Announce Earnings on Tuesday

Zoetis (NYSE:ZTS - Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect Zoetis to post earnings of $1.41 per share and revenue of $2.20 billion for the quarter. Zoetis has set its FY 2025 guidance at 6.000-6.100 EPS.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to analysts' expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, analysts expect Zoetis to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Zoetis Stock Performance

Shares of NYSE:ZTS traded down $0.68 during trading on Thursday, hitting $155.72. 1,930,312 shares of the stock traded hands, compared to its average volume of 2,477,451. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The company has a market cap of $69.48 billion, a price-to-earnings ratio of 28.47, a P/E/G ratio of 2.78 and a beta of 0.92. The company has a fifty day moving average price of $158.54 and a two-hundred day moving average price of $167.65. Zoetis has a 52-week low of $139.70 and a 52-week high of $200.33.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.28%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio (DPR) is 36.56%.

Insider Activity

In other news, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Zoetis stock. Brighton Jones LLC raised its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 180.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,629 shares of the company's stock after buying an additional 2,978 shares during the quarter. Brighton Jones LLC's holdings in Zoetis were worth $754,000 at the end of the most recent quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ZTS has been the subject of several recent analyst reports. Morgan Stanley cut their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a report on Friday, February 14th. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Piper Sandler boosted their price target on shares of Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Thursday, February 27th. Stifel Nicolaus cut their price target on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a report on Monday, April 14th. Finally, Barclays boosted their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a report on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $214.40.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.